Fulltext

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Bonnefoi, H. ; Litière, S. ; Piccart, M. ; MacGrogan, G. ; Fumoleau, P. ; Brain, E. ; Petit, T. ; Rouanet, P. ; Jassem, J. ; Moldovan, C. ; Bodmer, A. ; Zaman, K. ; Cufer, T. ; Campone, M. ; Luporsi, E. ; Malmström, P. ; Werutsky, G. ; Bogaerts, J. ; Bergh, J. ; Cameron, D. A.

In: Annals of Oncology, 2014, vol. 25, no. 6, p. 1128-1136

Ajouter à la liste personnelle
    Titre
    • Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
    Auteur
    • Bonnefoi, H.. Department of Medical Oncology, Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U916, Bordeaux, France
    • Litière, S.. European Organisation for Research and Treatment of Cancer (EORTC), Brussels
    • Piccart, M.. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
    • MacGrogan, G.. Department of Medical Oncology, Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U916, Bordeaux, France
    • Fumoleau, P.. Centre George-François Leclerc, Dijon
    • Brain, E.. Ensemble Hospitalier de L'Institut Curie, Hopital René Huguenin, St-Cloud
    • Petit, T.. Centre Paul Strauss, Strasbourg
    • Rouanet, P.. Centre Val D'Aurelle-Paul Lamarque, Montpellier, France
    • Jassem, J.. Medical University, Gdansk, Poland
    • Moldovan, C.. Centre Henri Becquerel, Rouen, France
    • Bodmer, A.. Geneva University Hospital, Geneva
    • Zaman, K.. Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
    • Cufer, T.. Institute of Oncology, Ljubljana
    • Campone, M.. Institut de Cancérologie de L'Ouest (ICO), Centre René Gauducheau, Nantes
    • Luporsi, E.. Centre Alexis Vautrin, Nancy, France
    • Malmström, P.. Department of Clinical Sciences, Lund University, Lund
    • Werutsky, G.. European Organisation for Research and Treatment of Cancer (EORTC), Brussels
    • Bogaerts, J.. European Organisation for Research and Treatment of Cancer (EORTC), Brussels
    • Bergh, J.. Swedish Breast Cancer Group (SweBCG), Stockholm
    • Cameron, D. A.. Cancer Services, Edinburgh University
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2014, vol. 25, no. 6, p. 1128-1136. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:299226
    Summary
    The present analysis, carried out in the context of a randomized phase III trial, confirms superior outcomes for breast cancer patients for whom chemotherapy induces pathological complete response (pCR) after adjusting for other important prognostic factors. In contrast, when tumours do not achieve pCR, patients have a higher risk of relapse. This effect is observed in all intrinsic subtypes and justifies the current interest in post-neoadjuvant trials